Heading to the stars in RAS driven cancers

A next generation category of KRAS inhibitors are emerging - W2W4

May 10, 2023

What will novel CAR-T cells look like in the future?

In a few years time the next generation CAR-T cell therapies are going to look and behave very…

March 9, 2023

Cool and emerging new concepts to watch out for in Gliomas

A look at some new developments in CAR-T cell therapy for gliomas

February 27, 2023

Diet as a drug

We have heard much over the last decade or so about the impact of the microbiome on responses to…

February 22, 2023

Thinking outside the Box

The next generation of CAR-T cell therapy will require out of the box thinking

February 20, 2023

The near term future in CAR-T cells is a’changing!

How base editing can transform the development of next gen CAR-T cell therapies

February 13, 2023

New directions in lymphomas

What will be the emerging products and regimens to watch out for in aggressive lymphomas?

January 31, 2023

Pointing the way forward

How can performance of T cell therapy be improved?

January 11, 2023

Kaizen in action

The evolving BMS-Celgene pipeline and what's coming next in new developmental twists

January 10, 2023

Caveat emptor

A hard look at the KRYSTAL-7 data presented at ESMO IO

December 7, 2022

Dancing with Cancer Cells

The beat goes on for synthetic lethal approaches

November 17, 2022

The art and science of a novel immunotherapy for solid tumours

Reprogramming T cell phenotype is becoming a hot topic in solid tumours and here's why...

October 28, 2022

Targeting MYC – trick or treat?

Beyond KRAS - targeting another of the four horsemen of the apocalypse

October 25, 2022

Going beyond PARP1/2 inhibition with novel approaches

Can we overcome resistance checkpoint blockade with novel approaches to DDR?

October 7, 2022

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022

Shoreline rides the CAR-NK wave at AACR22

First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22

July 7, 2022

The long and winding road to success

An emerging new and highly selective oncogenic target

June 30, 2022

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022

Talkin’ ’bout a Revolution

The continuous evolution of BCMA CAR-T cell therapy products and how they are doing

June 6, 2022

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022

Watch to watch out for at ASCO22

Hot or not - 5 early stage trials with different agents and targets

May 5, 2022

Are there challenging times ahead for KRAS inhibitor combinations?

A lion roar or whimper at the prospect of KRASi plus IO trials?

April 5, 2022

The paradox of immune cell populations and transcription factors

Can you have your immune cake and eat it?

March 23, 2022

Finding achilles heels to tackle cancer head on

Exploring new approaches to targeting cancer

January 20, 2022

Going after intractable cancer targets

It's time for an update on novel protein degraders

January 11, 2022

A different IO approach to tackling solid tumours

Can we improve the quality of T cells performance and boost outcomes?

January 12, 2022

Can C4 take protein degraders to new heights?

The intriguing science behind a novel protein degrader platform

January 10, 2022

The CAR-T cell therapy merry-go-round in aggressive lymphomas

A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study

December 14, 2021

Kaizen and the art of improving CAR-T cell performance

Part 2 of our mini-series on Next Generation CAR-T cells

December 14, 2021

Can we predict response to breast cancer therapy?

What can we learn from various breast cancer trials?

December 8, 2021

Tackling immunosuppression with a dual approach to TIGIT and adenosine

Do we need to target the adenosine fog as well as TIGIT in NSCLC?

June 24, 2021

Coming back full circle

Can a genomic signature help select patients more accurately for DDR therapies?

August 26, 2021

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021

A bridge to a broad and deep oncology pipeline

What are Novartis up to these days with their oncology pipeline and what are they excited about?

July 29, 2021

An authentic and novel approach to designing novel anti-cancer drugs

A look at why and how Relay's early oncology pipeline might be one to reckon with

July 26, 2021

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021

The interface of science, innovation, and imagination

What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?

July 13, 2021

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021

New developments in the protein degradation niche

Update on C4, Kymera, Novartis and Vividion

June 30, 2021

Tackling a hostile tumour microenvironment on multiple fronts

Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME

June 24, 2021

Are AI and machine learning alive or dead in oncology?

How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?

June 15, 2021

Shipping the KRAS line

Update on the Novartis SHP2 inhibitor at ASCO21

June 8, 2021

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021

Can a monoDAC hit the groove against IMiDs and CELMoDs?

What can we learn from C4 Therapeutics monoDAC, CFT7455?

April 28, 2021

The magic of making proteins disappear

A look at Kymera's protein degrader pipeline

July 21, 2020

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021

AACR21 Preview 5 Promising new developments in the PARP field and beyond

What's hot on the DDR front and PARP inhibitor space at AACR21?

March 25, 2021

The King of Kings

Capturing attention in the crowded protein degradation niche

March 11, 2021

Using bacteria as a trojan horse to target oncogenes

Degrading oncogenic proteins with novel bacterial approaches

March 1, 2021

The potential for a novel chemotherapy approach

How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types

February 25, 2021

How innovation in chemistry can transform anticancer therapy

A novel approach to chemistry can potentially transform a therapeutic modality against cancer

February 23, 2021

La Coupe de Feu

How do we unleash more cytotoxic T cells against a cancer with a high unmet medical need?

February 18, 2021

A critical look at the Amgen sotorasib data in KRAS G12C mutated lung cancers

Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore

February 1, 2021

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021

Looking through the window at the cilta-cel data

A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed

January 12, 2021

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

If it’s Tuesday it must be Belgium

It's time to turn our attention to novel TKI approaches in hematologic malignancies

December 8, 2020

What can we learn from Mirati’s adagrasib in lung and other cancers?

It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…

October 25, 2020
Hubble Space Telescope, Spitzer Space Telescope

On black holes and rising supernova stars in oncology

Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds

October 6, 2020

A phoenix rises from the ashes

A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape

September 23, 2020

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020

Targeting Glutamine for Cancer Immunometabolism

Can we influence T cell fitness and performance by manipulating metabolic processes?

August 11, 2020

Building up a storm against resistant solid tumours

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…

August 5, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

Will a novel way to target IL–18 be a winner?

Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?

June 29, 2020

Who is winning the CD20xCD3 Bispecific Race to Market?

An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.

June 15, 2020

A rock around the breast cancer clock

Highlights from various breast cancer trials and new pipeline developments

June 2, 2020

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020

A false dawn in adjuvant EGFR mutant lung cancer? Dr Ross Camidge provides a critical review of ADAURA

Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.

June 1, 2020

Reflections on bench to bedside progress

From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years

May 29, 2020

Highlighting an under-rated clinical development at ASCO20

Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)

May 14, 2020

Is the Arvinas PROTAC Proof of the Pudding?

What do we learn from the initial data with novel PROTAC technology?

May 13, 2020

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020

The next wave of IO agents for combination therapies

Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?

March 12, 2020

When everyone zigs, zag

Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?

March 10, 2020

Under the Radar

An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy

February 28, 2020

A look at Mirati in the context of the broader KRAS niche

An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche

February 25, 2020

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020

Whipping up a frenzy in CAR-T cell future developments

In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours

February 13, 2020

Quest for the Holy Grail of Cell Therapy

CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."

February 11, 2020

What does the next decade hold for CAR T cell therapy?

Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering

February 6, 2020

A delicate question of balance

Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain

February 5, 2020

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020

Lining up multiple approaches in AML

Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.

January 23, 2020

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020

Lining up new developments in the treatment of GVHD

Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.

January 13, 2020

The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020

Highlights and lowlights in HER2+ metastatic breast cancer at SABCS19

A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC

December 11, 2019

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15

Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma

November 11, 2019

The potential of innovative mouse models to recapitulate the microbiome of cancer patients

What new things will we learn about the microbiome at SITC19?

November 4, 2019

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019

Eyes on CAR-T Cell Therapy in Europe – Future Directions

There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.

October 17, 2019

Insights from KEYNOTE-522 in early stage TNBC

As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.

October 15, 2019

New directions in HR-positive breast cancer

Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?

October 14, 2019

PARP inhibition in metastatic prostate cancer

What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...

October 9, 2019

Crossing the Rubicon

Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC

October 8, 2019

Insights on osimertinib in 1L NSCLC from the lens of the FLAURA trial

A look at the FLAURA overall survival results and what we can learn from the phase 3 trial

September 28, 2019

Overcoming a hostile tumor microenvironment with Siglec-15

Is Siglec-15 a key target in overcoming immunosuppression in some cancer patients?

September 6, 2019

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019

Gerard Evan discusses inflammation and immune suppression in cancer

How do mission critical oncogenes cooperate and act in concert in cancer?

August 30, 2019

Why does Myc drive out T cells?

If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel

August 29, 2019

On the interaction between transcription factors and the immune system

A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...

August 26, 2019

New developments in Sarcoma

A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche

July 23, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019

How F-star are optimising bispecific antibodies for cancer treatment

Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?

July 10, 2019

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019

Dracarys! How T cell therapy is like Game of Thrones

Is T cell therapy like Game of Thrones?

July 1, 2019

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019

What’s new with Corvus Pharma?

New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...

June 11, 2019

Going back to basics

How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents

April 29, 2019

Challenges of targeting KRAS G12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019

Can Silverback increase the Firepower of TLR agonists?

A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche

May 9, 2019

Dancing with proteins

Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.

May 6, 2019

There is a deeper world than this

A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.

May 1, 2019

Chipping away at cancer

Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.

April 25, 2019

Incysus Targets GBM with Gamma Delta T Cells

Can gamma delta T cells be effective as a therapeutic in GBM?

April 23, 2019

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019

Targeting neutrophils for cancer immunotherapy

Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?

April 15, 2019

The Future of Cancer Immunotherapy Biomarkers

With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection

April 9, 2019

How confident can we be in the reproducibility of the IMpassion130 results in TNBC?

Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?

April 8, 2019

Could targeting Regulatory T cells be a game changer?

Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.

March 18, 2019

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019
TC BioPharm Office Building

TC BioPharm leads the way in allogeneic gamma delta T cells

TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020

March 4, 2019
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019

Window through the world of early STING agonist development

Targeting STING in cancer with a systemic small molecule approach? What's the story?

February 22, 2019

Can next generation STING agonism make a difference?

What does a next generation STING agonist look like and what issues is it attempting to address?

February 21, 2019

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019

Potential of CAR T cell therapy in CLL

How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.

December 10, 2018

SABCS18 An in-depth review of key breast cancer trials

A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18

December 7, 2018

Can CytomX’s Probody checkpoint beat the competition?

Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?

November 5, 2018

Iraj Ali leads the way at Achilles Therapeutics

Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens

October 31, 2018

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018

Is blood TMB ready for prime time?

With new data on the blood-based TMB test at ESMO, what can we learn about this approach?

October 29, 2018

Why are the SOLO1 data so compelling?

A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial

October 26, 2018
View of Cambridge and Charles River

A new prime and boost cell therapy for treating cancer?

Can we use technology to squeeze more out of B cells to generate an army of killer T cells?

October 17, 2018

ESMO18 Preview 5 – A look at the evolving Renal Cell Carcinoma landscape

The changing face of renal cell cancer from several perspectives

October 16, 2018

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018

Adapting TCR therapies for different solid tumours

An in-depth look at Adaptimmune's TCR T cell therapy program

July 10, 2018

Can we use exosomes for immune monitoring?

One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…

June 21, 2018

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018

A beautiful day

Update on TLR9 as a target and what we learn from the latest clinical data

June 12, 2018

Fitting it all together – what does the post ASCO Lung Cancer Landscape look like?

Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...

June 11, 2018

Will KEYNOTE-042 change the standard of care in lung cancer?

Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).

June 3, 2018

Development of Next Generation CAR T cell therapies

A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers

May 14, 2018

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018

A new inhibitory checkpoint target hits the clinic

Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic

May 7, 2018

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018

The PD-1 Gorilla is Back!

4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18

April 25, 2018

Can TMB help select patients for lung cancer therapy or not?

A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?

April 23, 2018

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

A look at NK cells – an interview with Dr Michael Caligiuri

A look at the history of NK cell development and where we're going in future with this IO approach

March 7, 2018

Potential of Exosomes in Pancreatic Cancer

A look at an emerging area for biomarkers and stealth cancer therapeutics

March 1, 2018

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018

Pathways to success targeting CD47-SIRPα

Insights from researchers in the CD47 niche - what do they really think?

February 20, 2018

Apalutamide is not a winner at ASCO GU

Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?

February 8, 2018

Go Forth and PROSPER

Interview with Dr Daniel George on Phase 3 PROSPER trial results

February 5, 2018

The STING and Metastasis Controversy Reignited

Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.

January 29, 2018

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018

How Obsidian could revolutionise CAR T cell therapy in solid tumours

A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours

January 10, 2018

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018

The science behind the venetoclax clinical trial strategy

Where is the venetoclax BCL-2 program going in hematologic malignancies?

December 18, 2017

ASH17 masterclass with Dr John Leonard on lymphomas

An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17

December 14, 2017

ASH17 Will MURANO impact the CLL landscape?

As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?

December 13, 2017

IMpower150 lung cancer trial provides a window to the Future of Immunotherapy

The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?

December 7, 2017

What can genomics and tumours teach us about cancer drug development?

A look at loss of heterozygosity and what it means for new lung cancer therapies

November 20, 2017

Why we should be cautiously optimistic about the cabiralizumab plus nivolumab data in pancreatic cancer

A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend

November 15, 2017

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017

SITC17 DAY 1 Highlights and Lowlights

A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.

November 10, 2017

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

Immunotherapy Possibilities in Pancreatic Cancer

A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?

October 5, 2017

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017

ESMO17 Day 4 Highlights and Lowlights

A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore

September 12, 2017

Is CD123 a good target in AML?

A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.

August 31, 2017

The dawn of a new beginning for Cellectis?

What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?

August 30, 2017

Waseem Qasim Pioneers Allogeneic CAR T Cell Therapy

Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?

August 29, 2017

A man on a Mission to #FinishCancer

Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?

August 28, 2017

How to revolutionize cancer immunotherapy trials

A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist

August 10, 2017

Exploring pre-existing immunity in cancer immunotherapy trials

A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17

August 8, 2017

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
Berlin Wall Museum

Can we use immunotherapy to treat or delay Alzheimers Disease?

How we could use our immune system against Alzheimer's?

July 20, 2017

Can epigenetic therapy boost cancer immunotherapy?

A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?

July 19, 2017

When targeted and immunotherapy worlds collide

A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.

July 6, 2017

Why did Atezolizumab fail in advanced Urothelial Bladder Cancer?

Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.

June 27, 2017

Gems from the ASCO17 Poster Hall Part 1

A look at how liver mets can negatively impact cancer immunotherapies

June 22, 2017

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017

Is 2017 the Year of the Cancer Vaccine?

A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.

February 21, 2017

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017

Do Exosomes Matter?

With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.

May 2, 2017

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017

Can Jonathan Lim ignite the TRK oncology space?

An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition

April 26, 2017

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017

What do we know about Resistance to Checkpoints in Lung Cancer?

Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts

April 20, 2017

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017

Dan Chen outlines his vision for the Future of Cancer Immunotherapy at AACR17

Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.

April 13, 2017

What does atezolizumab TNBC data presented at AACR17 tell us about breast cancer immunotherapy?

Interview with Professor Peter Schmid, Barts Cancer Institute.

April 10, 2017
Ira Mellman Dan Chen Authors of Cancer Immunity Cycle

Understanding the Cancer-Immune Set Point

A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.

February 22, 2017

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017

A completely novel approach to targeting hematologic malignancies

A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.

February 15, 2017

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017

Targeting the tumour environment in Lymphomas

What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.

February 6, 2017

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017

Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017

Promising new agents to watch out for in Chronic Lymphocytic Leukemia

A look at some promising agents in new product development emerging in early CLL trials

January 6, 2017

The Changing CLL Landscape Part 1

How are recently approved novel therapies impacting the CLL landscape and where are we going next?

January 5, 2017

Does Polatuzumab Vedotin have Potential in Lymphomas?

A look at the latest data for a CD79b targeted ADC in lymphomas

January 4, 2017

How the Leukemia Lymphoma Society plans to Beat AML

Tackling heterogeneity in older people with AML using novel targeted therapies.

December 21, 2016

LeonardList showcases 10 Lymphoma Abstracts at ASH16

#LeonardList showcases 10 Lymphoma Abstracts at ASH16

December 19, 2016

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016

How do you calculate Immunoscore? A tour of HalioDx

Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay

October 3, 2016
Dr Eric Pamer presenting at CIML40

Manipulating the Microbiota to Improve Clinical Outcomes. An interview with Eric Pamer

Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.

September 28, 2016

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016

François Romagné Accelerates Cancer Immunotherapy Innovation in Marseille

Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.

September 21, 2016

Innate Pharma at an Inflexion Point: An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016

HalioDX CEO Vincent Fert outlines commercial strategy for Immunoscore in US and Europe

Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.

September 14, 2016

Modelling the Tumour Microenvironment

Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer

August 22, 2016

PsiOxus is a cancer immunotherapy company to watch – Part 2 of an interview with CEO John Beadle

Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.

August 17, 2016

Can PsiOxus become a world leading immuno-oncolytic virus company?

An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours

August 16, 2016

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016

Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016

The Next Big Wave in Multiple Myeloma

How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?

February 11, 2016

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016

Midostaurin in AML – Better Late than Never!

An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.

January 6, 2016

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016
ASH15 Late Breaker Session

New Treatments for CLL with Deletions in 17p

A look at the new CLL 17p deletion data at ASH in the late breaker session

January 4, 2016

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015

Is ocrelizumab a game changer in MS?

At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.

October 11, 2015

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015
Dr Holbrook Kohrt

Holbrook Kohrt Leads the Way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015

Impact of TERRAIN trial on European Prostate Cancer treatment landscape #EAU15

The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.

March 24, 2015

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015

Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?

At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.

November 18, 2014
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014

ASCO 2014 Diffuse Large B Cell Lymphoma DLBCL Progress

Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.

June 30, 2014

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014

Super Enhancers – what are they and why do they matter in cancer research?

Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.

April 14, 2014

ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?

The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?

February 10, 2014

ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data

Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial

January 28, 2014

Can Agios score a winner with their anti-cancer metabolism molecules?

Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?

January 13, 2014

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013

FDA Breakthrough Therapy Designation Benefits – part 2 of an interview with John Jenkins

FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.

November 26, 2013

Understanding the Breakthrough Therapy Designation – Part 1 of an interview with FDA New Drugs Director John Jenkins

John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?

November 15, 2013

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013

ASCO 2013 Video Interview with Dr Susan O’Brien on CLL new drugs in development

It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.

June 10, 2013